Continued monotherapy with metformin, compared with a sulfonylurea, is associated with a lower risk for major adverse cardiovascular events (MACE) among patients with type 2 diabetes who experienced reduced kidney function.
New review identifies benefits of sodium-glucose co-transporter-2 (SGLT2) inhibitors at almost all levels of kidney function.
Machine learning algorithms can aid in assessment of renal histopathology
Testing for acid load needed in patients with diabetes taking sodium-glucose cotransporter-2 inhibitors
Studies document renal benefits of canagliflozin, dapagliflozin, empagliflozin, and dulaglutide
In a phase 2 study of patients with early diabetic nephropathy, esaxerenone decreased microalbuminuria in a dose-dependent manner over 12 weeks compared with placebo.
In the REWIND trial of type 2 diabetes patients, dulaglutide modestly reduced cardiovascular events and progression of kidney disease for at least 5 years.
Ertugliflozin may be protective of renal function in patients with type 2 diabetes.
Protective effect is driven largely by a sustained 40% decrease in estimate glomerular filtration rate to below 60 mL/min/1.73 m2.
Per the ADA update, clinicians should consider prescribing a SGLT2 inhibitor in type 2 diabetes patients with diabetic nephropathy.
